FundLens
41
Pharma & HealthcareAvoid

ABSL Pharma And Healthcare

Aditya Birla Sun Life · Direct–Growth · rank #11 of 19 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
19.4%
+18.6% vs index
3 Years
19.9%
+8.4% vs index
5 Years
15.9%
+5.8% vs index
Since launch
21.1%

Year-by-year performance

last entry = YTD
2021
+21.4%
2022
-11.3%
2023
+39.6%
2024
+37.7%
2025
-3.1%
2026
+21.3%

Why this score

ABSL Pharma And Healthcare scores 41/100 — #11 of 19 Pharma & Healthcare fund (Avoid). The main drag is its 3y return (better than only 29% of peers).

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

3Y return19.95% · 29th percentile in category
Alpha1.45 · 9th percentile in category
5Y return15.94% · 45th percentile in category
Fund size1087.92 Cr · 55th percentile in category
Sharpe ratio0.97 · 47th percentile in category
Volatility15.38 · 47th percentile in category

Top holdings

top 5 = 35.4% of portfolio
1.Torrent Pharmaceuticals Ltd8.83%
2.Sun Pharmaceutical Industries Ltd8.35%
3.Cipla Ltd7.1%
4.Apollo Hospitals Enterprise Ltd6.6%
5.Sai Life Sciences Ltd.4.54%

40 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds